Navigation Links
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Date:6/1/2009

Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy

ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that at the poster and discussion session of the Lymphoma and Plasma Cell Disorders Section at the 2009 American Society of Clinical Oncology ("ASCO") Annual Meeting, new subgroup analysis data were reviewed from the phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") demonstrating the effectiveness of pixantrone as therapy in patients with aggressive non-Hodgkin's lymphoma ("NHL") for whom anthracycline and related drugs are typically not to be used due to a high risk of cardiac toxicity, including cardiac failure.

Twenty-five of the 70 patients in the PIX 301 EXTEND trial had received prior cumulative doxorubicin doses in excess of the standard 300 mg/m2 associated with six cycles of first line CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. The median prior exposure of these patients, most of whom had received an anthracycline as part of a salvage regimen, was 386 mg/m2 (with a range of 306 mg/m2 to 778 mg/m2). Following treatment with pixantrone, ten of these 25 patients (40%) achieved a confirmed complete remission ("CR"), unconfirmed remission ("CRu") or partial remission ("PR") (CR=2, CRu= 5, 28%; PR=3, 12%) The lifetime cumulative doxorubicin equivalent dose following pixantrone was 579 mg/m2 (with a range of 361 mg/m2 to 1003 mg/m2). No patient developed a severe reduction (>=20%) in left ventricular ejection fraction (LVEF) and only one patient developed congestive heart failure (CHF). The total cumulative doxorubicin equivalent exposure per treatment cycle for all 68 patients treated with pixantrone is noted in the table below:

           Treatment 
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
3. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
4. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
7. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
10. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
11. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), a global ... epilepsy, today announced it will participate in the 33 rd ... 2015, in San Francisco . ... will speak at 11:00 AM Pacific Time.  A live audio ... the Investor Relations link on the Cyberonics home page at ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Investment Analysis of the US Medical Device Sector 2
... ORLEANS, June 16 Cardinal Health, a,global provider ... and,productivity of health care, today announced that it ... (PET),radiopharmaceuticals for clinical trials., The company,s new ... at the Society of Nuclear Medicine,s (SNM) 55th ...
... the efficacy of RESPeRATE while highlighting ... BERLIN and NEW YORK, June 16 European Society ... Ltd., a medical device,company publicly traded on the Tel-Aviv ... studies and analysis highlighting RESPeRATE,-- the only medical device ...
Cached Medicine Technology:Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials 2Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 2Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 3Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 4
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... esthetician, Karen,Dunlap, has developed an advanced anti-aging procedure ... most nutritious and powerful food,in the world -- ... and,nature, Dunlap discovered that topical application of the ... Her new signature facial, the,Acai Berry Anti-Aging Facial, ...
... 4 Trust for America,s,Health warns that the proposed ... and Prevention (CDC) in the president,s fiscal year 2009,budget ... the budget,for CDC would fall to a six year ... healthcare costs are skyrocketing, we should be,investing more to ...
... February 4, 2008 The U.S. Pharmacopeia (USP) ... Spanish edition of its core compendia, the United ... available for purchase. The official edition for 2008, ... more than 4,000 quality pharmaceuticals, excipients, dietary supplements, ...
... N.J., Feb. 4 Milestone Scientific,Inc. (OTC Bulletin ... today announced that Scott Mahnken has joined the,Company,s ... with,developing and managing a wide range of strategic ... brand awareness,and drive sales growth, Mahnken will report ...
... AUDUBON, Pa., Feb. 4 Globus Medical, Inc., the ... announced,record revenue for the year ending December 31, 2007. ... of 50 percent over the $82 million,it achieved in ... significant milestones achieved,by the Company during 2007. "This has ...
... on The Burden of Rheumatoid Arthritis and Patient Access ... Economics (Sweden), the University of Lund (Sweden) and the ... highest cost in rheumatoid arthritis results from patients having ... The study has just been published online in ...
Cached Medicine News:Health News:Breakthrough 'Acai Berry Anti-Aging Facial' Applies Benefits of Nature's Super-Food to the Skin 2Health News:Cuts to HHS Could Leave Americans' Health in Critical Condition, TFAH Says; New Poll Shows Americans Believe Disease Prevention is Key to Reducing Healthcare Costs 2Health News:USP publishes Spanish edition of United States Pharmacopeia and National Formulary 2Health News:Milestone Scientific Appoints Dental Industry Veteran Scott Mahnken as New Director of Marketing 2Health News:Milestone Scientific Appoints Dental Industry Veteran Scott Mahnken as New Director of Marketing 3Health News:Globus Medical Announces Record Revenue for 2007 2Health News:Rheumatoid arthritis sends many into early retirement 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States....
... The Surgical Foam Headrest automatically secures ... patient as comfortable as possible. Several ... adjust for any head size from ... be autoclaved when necessary. From surgical ...
... These focusing prismatic telescope are available in ... and 4.2x can be spectacle mounted or supplied ... The 8.25x is a hand held telescope. ,Small ... ideal for reading signposts, bus numbers, etc. ...
Medicine Products: